Hilary Hoffman is an associate in the FDA Regulatory Group. She represents life sciences companies on matters spanning the entire product development lifecycle, including clinical development programs, product classification analyses, marketing authorization submissions, and post-market compliance. She counsels clients in connection with acquisitions, regulatory compliance, government enforcement actions, private litigation, and internal investigations.
Hilary works with clients in a variety of life sciences industries, including pharmaceuticals, medical devices, in vitro diagnostics, laboratory developed tests, biologics, and dietary supplements. She regularly counsels clients on topics such as good manufacturing practices, data integrity, clinical trial requirements, advertising and promotion, post-marketing obligations, and regulatory filings. Hilary also assists clients in preparing for regulatory inspections and drafting responses to FDA Form 483s and Warning Letters. She also has advised clinical laboratories, pharmacies, and healthcare group practices in False Claims Act qui tam litigation and Federal Anti-Kickback Statute investigations.
DLA Piper is a global law firm operating through various separate and distinct legal entities. For further information about these entities and DLA Piper's structure, please refer to the Legal Notices page of this website. All rights reserved. Attorney advertising.
Unsolicited e-mails and information sent to DLA Piper or the independent DLA Piper Relationship firms will not be considered confidential, may be disclosed to others, may not receive a response, and do not create a lawyer-client relationship with DLA Piper or any of the DLA Piper Relationship firms. Please do not include any confidential information in this message. Also, please note that our lawyers do not seek to practice law in any jurisdiction in which they are not properly permitted to do so.